{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T18:04:39Z","timestamp":1772906679864,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CV Wissenschaftsf\u00f6rderung Essen"},{"name":"ELAN (Essener Ausbildungsprogramm \"Labor und Wissenschaft\" f\u00fcr den aerztlichen Nachwuchs)."},{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Podocytes are highly specialized cells playing a key role in the filtration function of the kidney. A damaged podocyte ultrastructure is associated with a reorganization of the actin cytoskeleton and accompanied with a loss of adhesion to the glomerular basement membrane leading to proteinuria in many forms of glomerular diseases, e.g. nephrotic syndrome. If the first-line therapy with glucocorticoids fails, alternative immunosuppressive agents are used, which are known to have the potential to stabilize the actin cytoskeleton. A new option for preventing relapses in steroid dependent nephrotic syndrome is the monoclonal antibody rituximab, which, in addition to its B-cell depleting effect, is assumed to have direct effects on podocytes. We here provide data on the non-immunological <jats:italic>off-target<\/jats:italic> effects of the immunosuppressant rituximab on podocyte structure and dynamics in an in vitro puromycin aminonucleoside model of podocyte injury. A conditionally immortalized human podocyte cell line was used. Differentiated podocytes were treated with puromycin aminonucleoside and rituximab. Our studies focussed on analyzing the structure of the actin cytoskeleton, cellular adhesion and apoptosis using immunofluorescence staining and protein biochemistry methods. Treatment with rituximab resulted in a stabilization of podocyte actin stress fibers in the puromycin aminonucleoside model, leading to an improvement in cell adhesion. A lower apoptosis rate was observed after parallel treatment with puromycin aminonucleoside and rituximab visualized by reduced nuclear fragmentation. Consistent with this data, Western-blot analyses demonstrated that rituximab directly affects the caspase pathways by inhibiting the activation of Caspases-8, -9 and -3, suggesting that rituximab may inhibit apoptosis. In conclusion, our results indicate an important role of the immunosuppressant rituximab in terms of stability and morphogenesis of podocytes, involving apoptosis pathways. This could help to improve therapeutical concepts for patients with proteinuria mediated by diseased podocytes.<\/jats:p>","DOI":"10.1038\/s41598-022-16333-w","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T10:03:15Z","timestamp":1658224995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Protective effects of rituximab on puromycin-induced apoptosis, loss of adhesion and cytoskeletal alterations in human podocytes"],"prefix":"10.1038","volume":"12","author":[{"given":"Stefanie","family":"Jeruschke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Alex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Friedrich","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"issue":"15","key":"16333_CR1","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJM197804132981507","volume":"298","author":"BM Brenner","year":"1978","unstructured":"Brenner, B. M., Hostetter, T. H. & Humes, H. D. Molecular basis of proteinuria of glomerular origin. N. Engl. J. Med. 298(15), 826\u2013833 (1978).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"16333_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1172\/JCI109354","volume":"63","author":"HG Rennke","year":"1979","unstructured":"Rennke, H. G. & Venkatachalam, M. A. Glomerular permeability of macromolecules. Effect of molecular configuration on the fractional clearance of uncharged dextran and neutral horseradish peroxidase in the rat. J. Clin. Invest. 63(4), 713\u2013717 (1979).","journal-title":"J. Clin. Invest."},{"key":"16333_CR3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1111\/j.1440-1797.2007.00876.x","volume":"Suppl 3","author":"K Asanuma","year":"2007","unstructured":"Asanuma, K., Yanagida-Asanuma, E., Takagi, M., Kodama, F. & Tomino, Y. The role of podocytes in proteinuria. Nephrology (Carlton). Suppl 3, S15\u2013S20 (2007).","journal-title":"Nephrology (Carlton)."},{"issue":"5","key":"16333_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000072917","volume":"23","author":"L Barisoni","year":"2003","unstructured":"Barisoni, L. & Mundel, P. Podocyte biology and the emerging understanding of podocyte diseases. Am. J. Nephrol. 23(5), 353\u2013360 (2003).","journal-title":"Am. J. Nephrol."},{"issue":"12","key":"16333_CR5","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/sj.ki.5000410","volume":"69","author":"SJ Shankland","year":"2006","unstructured":"Shankland, S. J. The podocyte\u2019s response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int. 69(12), 2131\u20132147 (2006).","journal-title":"Kidney Int."},{"key":"16333_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ki.2009.424","volume":"77","author":"P Mundel","year":"2010","unstructured":"Mundel, P. & Reiser, J. Proteinuria: An enzymatic disease of the podocyte?. Kidney Int. 77, 571\u2013580 (2010).","journal-title":"Kidney Int."},{"issue":"11","key":"16333_CR7","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2215\/CJN.01190210","volume":"5","author":"AK B\u00fcscher","year":"2010","unstructured":"B\u00fcscher, A. K. et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 5(11), 2075\u20132084 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"16333_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2215\/CJN.07370715","volume":"11","author":"AK B\u00fcscher","year":"2016","unstructured":"B\u00fcscher, A. K. et al. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 11(2), 245\u2013253 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"16333_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40124-014-0065-5","volume":"3","author":"K Iijima","year":"2015","unstructured":"Iijima, K., Sako, M. & Nozu, K. Rituximab treatment for nephrotic syndrome in children. Curr. Pediatr. Rep. 3(1), 71\u201377 (2015).","journal-title":"Curr. Pediatr. Rep."},{"key":"16333_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000348470","volume":"181","author":"X Wang","year":"2013","unstructured":"Wang, X. & Xu, H. New insights into treatment of nephrotic syndrome in children. Contrib. Nephrol. 181, 119\u2013130 (2013).","journal-title":"Contrib. Nephrol."},{"issue":"9","key":"16333_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14(9), 931\u2013938 (2008).","journal-title":"Nat. Med."},{"issue":"85","key":"16333_CR12","doi-asserted-by":"publisher","first-page":"8546","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3(85), 8546 (2011).","journal-title":"Sci. Transl. Med."},{"key":"16333_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055980","volume":"8","author":"S Jeruschke","year":"2013","unstructured":"Jeruschke, S. et al. Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling. PLoS ONE 8, e55980 (2013).","journal-title":"PLoS ONE"},{"issue":"2","key":"16333_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.krcp.2015.03.003","volume":"34","author":"TH Yoo","year":"2015","unstructured":"Yoo, T. H. & Fornoni, A. Nonimmunologic targets of immunosuppressive agents in podocytes. Kidney Res. Clin. Pract. 34(2), 69\u201375 (2015).","journal-title":"Kidney Res. Clin. Pract."},{"issue":"7","key":"16333_CR15","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz, K., Dotsch, J., Rascher, W. & Stachel, D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr. Nephrol. 19(7), 794\u2013797 (2004).","journal-title":"Pediatr. Nephrol."},{"issue":"12","key":"16333_CR16","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati, A. et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: Multicentric report. Clin. J. Am. Soc. Nephrol. 5(12), 2207\u20132212 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"16333_CR17","first-page":"249","volume":"7","author":"H Otukesh","year":"2013","unstructured":"Otukesh, H., Hoseini, R., Rahimzadeh, N. & Fazel, M. Rituximab in the treatment of nephrotic syndrome: A systematic review. Iran. J. Kidney Dis. 7(4), 249\u2013256 (2013).","journal-title":"Iran. J. Kidney Dis."},{"issue":"3","key":"16333_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.5114\/ceji.2017.70976","volume":"42","author":"K Popko","year":"2017","unstructured":"Popko, K., G\u00f3rska, E. & Ku\u017ama-Mroczkowska, E. Effectiveness of rituximab in nephrotic syndrome treatment. Cent. Eur. J. Immunol. 42(3), 313\u2013317 (2017).","journal-title":"Cent. Eur. J. Immunol."},{"issue":"47","key":"16333_CR19","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2013","unstructured":"Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22(47), 7359\u20137368 (2013).","journal-title":"Oncogene"},{"issue":"7","key":"16333_CR20","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3174\/ajnr.A2142","volume":"31","author":"DT Selewski","year":"2010","unstructured":"Selewski, D. T., Shah, G. V., Mody, R. J., Rajdev, P. A. & Mukherji, S. K. Rituximab (rituxan). AJNR Am. J. Neuroradiol. 31(7), 1178\u20131180 (2010).","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"5","key":"16333_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nri1838","volume":"6","author":"JC Edwards","year":"2006","unstructured":"Edwards, J. C. & Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6(5), 394\u2013403 (2006).","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"16333_CR22","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani, P. et al. Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial. J. Am. Soc. Nephrol. 26(9), 2259\u20132266 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"16333_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1681\/ASN.V133630","volume":"13","author":"MA Saleem","year":"2002","unstructured":"Saleem, M. A. et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J. Am. Soc. Nephrol. 13(3), 630\u2013638 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9","key":"16333_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137043","volume":"10","author":"S Jeruschke","year":"2015","unstructured":"Jeruschke, S. et al. Everolimus stabilizes podocyte microtubules via enhancing TUBB2B and DCDC2 expression. PLoS ONE 10(9), e0137043 (2015).","journal-title":"PLoS ONE"},{"issue":"11","key":"16333_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027457","volume":"6","author":"S Kummer","year":"2011","unstructured":"Kummer, S. et al. Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo. PLoS ONE 6(11), e27457 (2011).","journal-title":"PLoS ONE"},{"key":"16333_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg, M. S., Walshe, C. A., Ivanov, A. O. & Glennie, M. J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140\u2013174 (2005).","journal-title":"Curr. Dir. Autoimmun."},{"key":"16333_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12865-015-0113-0","volume":"16","author":"CP Corkum","year":"2015","unstructured":"Corkum, C. P. et al. Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT) and standard density gradient. BMC Immunol. 16, 48 (2015).","journal-title":"BMC Immunol."},{"key":"16333_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1146\/annurev-physiol-020911-153238","volume":"74","author":"A Greka","year":"2012","unstructured":"Greka, A. & Mundel, P. Cell biology and pathology of podocytes. Annu. Rev. Physiol. 74, 299\u2013323 (2012).","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"16333_CR29","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1159\/000314668","volume":"116","author":"S Takeuchi","year":"2010","unstructured":"Takeuchi, S. et al. The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis. Nephron. Exp. Nephrol. 116(1), e3-10 (2010).","journal-title":"Nephron. Exp. Nephrol."},{"key":"16333_CR30","doi-asserted-by":"publisher","first-page":"32087","DOI":"10.1038\/srep32087","volume":"6","author":"X Shen","year":"2016","unstructured":"Shen, X. et al. Calcineurin inhibitors cyclosporin A and tacrolimus protect against podocyte injury induced by puromycin aminonucleoside in rodent models. Sci. Rep. 6, 32087 (2016).","journal-title":"Sci. Rep."},{"issue":"1","key":"16333_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jmi.12133","volume":"255","author":"N Atale","year":"2014","unstructured":"Atale, N., Gupta, S., Yadav, U. C. & Rani, V. Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques. J. Microsc. 255(1), 7\u201319 (2014).","journal-title":"J. Microsc."},{"issue":"4","key":"16333_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a008656","volume":"5","author":"DR McIlwain","year":"2013","unstructured":"McIlwain, D. R., Berger, T. & Mak, T. W. Caspase functions in cell death and disease. Cold Spring Harb. Perspect. Biol. 5(4), a008656 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"3","key":"16333_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ki.1991.232","volume":"40","author":"A Koyama","year":"1991","unstructured":"Koyama, A., Fujisaki, M., Kobayashi, M., Igarashi, M. & Narita, M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 40(3), 453\u2013460 (1991).","journal-title":"Kidney Int."},{"issue":"11","key":"16333_CR34","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1177\/0300060518782017","volume":"46","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Cyclophosphamide versus cyclosporine A therapy in steroid-resistant nephrotic syndrome: A retrospective study with a mean 5-year follow-up. J. Int. Med. Res. 46(11), 4506\u20134517 (2018).","journal-title":"J. Int. Med. Res."},{"issue":"3","key":"16333_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","volume":"28","author":"RM Lombel","year":"2013","unstructured":"Lombel, R. M., Gipson, D. S. & Hodson, E. M. Treatment of steroid-sensitive nephrotic syndrome: New guidelines from KDIGO. Pediatr. Nephrol. 28(3), 415\u2013426 (2013).","journal-title":"Pediatr. Nephrol."},{"issue":"6","key":"16333_CR36","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani, P. et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: A randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6(6), 1308\u20131315 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"16333_CR37","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti, P. et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 25(4), 850\u2013863 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"16333_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12519-014-0453-5","volume":"10","author":"L Sun","year":"2014","unstructured":"Sun, L. et al. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: A prospective observational study in Shanghai. World J. Pediatr. 10(1), 59\u201363 (2014).","journal-title":"World J. Pediatr."},{"key":"16333_CR39","first-page":"CD002290","volume":"4","author":"NG Larkins","year":"2020","unstructured":"Larkins, N. G., Liu, I. D., Willis, N. S., Craig, J. C. & Hodson, E. M. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst. Rev. 4, CD002290 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"16333_CR40","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1097\/01.ASN.0000039661.06947.FD","volume":"13","author":"P Mundel","year":"2002","unstructured":"Mundel, P. & Shankland, S. J. Podocyte biology and response to injury. J. Am. Soc. Nephrol. 13(12), 3005\u20133015 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"16333_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddmod.2014.06.003","volume":"11","author":"BJ Lim","year":"2014","unstructured":"Lim, B. J., Yang, H. C. & Fogo, A. B. Animal models of regression\/progression of kidney disease. Drug Discov. Today Dis. Models. 11, 45\u201351 (2014).","journal-title":"Drug Discov. Today Dis. Models."},{"issue":"2","key":"16333_CR42","doi-asserted-by":"publisher","first-page":"F213","DOI":"10.1152\/ajprenal.90421.2008","volume":"296","author":"JW Pippin","year":"2009","unstructured":"Pippin, J. W. et al. Inducible rodent models of acquired podocyte diseases. Am. J. Physiol. Renal. Physiol. 296(2), F213\u2013F229 (2009).","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"4","key":"16333_CR43","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/sj.ki.5002311","volume":"72","author":"N Eto","year":"2007","unstructured":"Eto, N. et al. Podocyte protection by darbepoetin: Preservation of the cytoskeleton and nephrin expression. Kidney Int. 72(4), 455\u2013463 (2007).","journal-title":"Kidney Int."},{"issue":"6","key":"16333_CR44","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/j.1523-1755.2005.00723.x","volume":"68","author":"RF Ransom","year":"2005","unstructured":"Ransom, R. F., Lam, N. G., Hallett, M. A., Atkinson, S. J. & Smoyer, W. E. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int. 68(6), 2473\u20132483 (2005).","journal-title":"Kidney Int."},{"issue":"16","key":"16333_CR45","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1110813","volume":"366","author":"C Has","year":"2012","unstructured":"Has, C. et al. Integrin \u03b13 mutations with kidney, lung, and skin disease. N. Engl. J. Med. 366(16), 1508\u20131514 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"16333_CR46","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000046097","volume":"89","author":"M Hara","year":"2001","unstructured":"Hara, M., Yanagihara, T. & Kihara, I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 89(3), 342\u2013347 (2001).","journal-title":"Nephron"},{"issue":"3","key":"16333_CR47","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1046\/j.1523-1755.2001.060003957.x","volume":"60","author":"YH Kim","year":"2001","unstructured":"Kim, Y. H. et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int. 60(3), 957\u2013968 (2001).","journal-title":"Kidney Int."},{"issue":"1","key":"16333_CR48","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1159\/000066647","volume":"93","author":"H Goto","year":"2003","unstructured":"Goto, H. et al. Renal alpha-actinin-4: Purification and puromycin aminonucleoside-binding property. Nephron Exp. Nephrol. 93(1), e27-35 (2003).","journal-title":"Nephron Exp. Nephrol."},{"issue":"6","key":"16333_CR49","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1172\/JCI200112367","volume":"108","author":"M Schiffer","year":"2001","unstructured":"Schiffer, M. et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Invest. 108(6), 807\u2013816 (2001).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"16333_CR50","first-page":"21","volume":"20","author":"MS Matovinovi\u0107","year":"2009","unstructured":"Matovinovi\u0107, M. S. 3. Podocyte injury in glomerular diseases. EJIFCC. 20(1), 21\u201327 (2009).","journal-title":"EJIFCC."},{"issue":"5","key":"16333_CR51","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ajpath.2013.06.033","volume":"183","author":"H Liapis","year":"2013","unstructured":"Liapis, H., Romagnani, P. & Anders, H. J. New insights into the pathology of podocyte loss: Mitotic catastrophe. Am. J. Pathol. 183(5), 1364\u20131374 (2013).","journal-title":"Am. J. Pathol."},{"issue":"1","key":"16333_CR52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/nep.12737","volume":"22","author":"Y Takahashi","year":"2017","unstructured":"Takahashi, Y., Ikezumi, Y. & Saitoh, A. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes. Nephrology (Carlton). 22(1), 49\u201357 (2017).","journal-title":"Nephrology (Carlton)."},{"issue":"3","key":"16333_CR53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00262-004-0599-4","volume":"54","author":"E Cittera","year":"2005","unstructured":"Cittera, E. et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol. Immunother. 54(3), 273\u2013286 (2005).","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"16333_CR54","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1681\/ASN.2010090963","volume":"22","author":"T Matsusaka","year":"2011","unstructured":"Matsusaka, T. et al. Podocyte injury damages other podocytes. J. Am. Soc. Nephrol. 22(7), 1275\u20131285 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"16333_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5527\/wjn.v6.i5.221","volume":"6","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi, H. Podocyturia: Potential applications and current limitations. World J. Nephrol. 6(5), 221\u2013228 (2017).","journal-title":"World J. Nephrol."},{"issue":"17","key":"16333_CR56","first-page":"5480","volume":"63","author":"HT Chan","year":"2003","unstructured":"Chan, H. T. et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 63(17), 5480\u20135489 (2003).","journal-title":"Cancer Res."},{"issue":"5","key":"16333_CR57","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1182\/blood.V97.5.1392","volume":"97","author":"MA Ghetie","year":"2001","unstructured":"Ghetie, M. A., Bright, H. & Vitetta, E. S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97(5), 1392\u20131398 (2001).","journal-title":"Blood"},{"issue":"12","key":"16333_CR58","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay, J. et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95(12), 3900\u20133908 (2000).","journal-title":"Blood"},{"issue":"2","key":"16333_CR59","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1096\/fj.201600618R","volume":"31","author":"A Ahmad","year":"2017","unstructured":"Ahmad, A. et al. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes. Faseb J. 31(2), 771\u2013780 (2017).","journal-title":"Faseb J."},{"issue":"5","key":"16333_CR60","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0955-0674(00)00251-9","volume":"13","author":"SM Frisch","year":"2001","unstructured":"Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13(5), 555\u2013562 (2001).","journal-title":"Curr. Opin. Cell Biol."},{"issue":"24","key":"16333_CR61","doi-asserted-by":"publisher","first-page":"11704","DOI":"10.1158\/0008-5472.CAN-07-1906","volume":"67","author":"D Finlay","year":"2007","unstructured":"Finlay, D. & Vuori, K. Novel noncatalytic role for caspase-8 in promoting SRC-mediated adhesion and Erk signaling in neuroblastoma cells. Cancer Res. 67(24), 11704\u201311711 (2007).","journal-title":"Cancer Res."},{"issue":"24","key":"16333_CR62","doi-asserted-by":"publisher","first-page":"11505","DOI":"10.1158\/0008-5472.CAN-07-5755","volume":"67","author":"J Senft","year":"2007","unstructured":"Senft, J., Helfer, B. & Frisch, S. M. Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res. 67(24), 11505\u201311509 (2007).","journal-title":"Cancer Res."},{"issue":"3","key":"16333_CR63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1681\/ASN.V123413","volume":"12","author":"N Endlich","year":"2001","unstructured":"Endlich, N. et al. Podocytes respond to mechanical stress in vitro. J. Am. Soc. Nephrol. 12(3), 413\u2013422 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"16333_CR64","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1038\/s41467-019-11577-z","volume":"10","author":"A Petrosyan","year":"2019","unstructured":"Petrosyan, A. et al. A glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier. Nat. Commun. 10(1), 3656 (2019).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16333-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16333-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16333-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:37:48Z","timestamp":1669351068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16333-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16333"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16333-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12297"}}